AZD-9291 Mesylate; Osimertinib Mesylate CAS 1421373-66-1

Khoom Piav Qhia

Cov Khoom Npe: AZD-9291 Mesylate; Osimertinib Mesylate CAS TSIS: 1421373-66-1

Txhais:

AZD-9291 (Mesylate);

N- (2 - ((2- (dimethylamino) ethyl) (methyl) amino) -4-methoxy-5 - ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino ) phenyl) acrylamide methanesulfonate;

N- [2 - [[2- (Dimethylamino) ethyl] methylamino] -4-methoxy-5 - [[4- (1-methyl-1H-indol-3-yl) -2-pyrimidinyl] amino] phenyl] - 2-propenamide methanesulfonate;

Tshuaj& Lub cev nqaij daim tawv

Cov tsos: daj khoom.

Ntsuas: ≥ 99. 5%

Lub Kaum Ib Hlis 13, 2015, Asmeskas FDA tau pom zoo rau cov npe ntawm osimertinib qhov ncauj tshuaj, cov tshuaj tshiab ntawm AstraZeneca hauv tebchaws Askiv, nyob rau hauv lub npe lag luam ntawm tagrisso. Nws yog siv rau kev kho mob ntawm cov neeg tsis mob qog nqaij hlav cancer hauv hlwb tsis zoo ntawm cov neeg mob cov neeg mob cov tshuaj lom neeg hloov kev tiv thaiv kab mob kev loj hlob (EGFR) T 790 M cov txheej txheem lossis kev tawm tsam lwm cov tshuaj tiv thaiv kab mob EGFR. Nws yog qhov tsim nyog los kuaj xyuas seb puas yog T 790 M hloov tshwm sim hauv cov neeg mob EGFR inhibitor osimoltinib ua ntej kev siv tshuaj. Tsuas yog cov neeg mob uas tsis mob qog nqaij hlav cancer nrog T 790 M hloov pauv tuaj yeem tau txais hom phiaj kho nrog ocimotinib.

Yog tias koj txaus siab rau peb cov khoom lossis muaj lus nug, thov koj xav tiv tauj peb!

Cov khoom lag luam hauv qab patent yog muab rau R& D lub hom phiaj nkaus xwb. Txawm li cas los xij, lub luag haujlwm kawg tau txiav txim siab nrog cov neeg yuav khoom.

Cim npe nrov: azd-9291 mesylate; osimertinib mesylate cas 1421373-66-1, tuam ntxhab, lwm tus neeg, Hoobkas, yuav, hauv Tshuag

• Tug: N1 - [2 - (Dimethylamino) ethyl] -5-methoxy-N1-methyl-N4- [4- (1-methyl-1H-indol-3-yl) - 2 - pyrimidinyl] -1, 2, 4-benzenetriamine CAS 14 2 137 2 - 66-8
• Tom ntej: Osimertinib CAS 1421373-65-0